| 梁 晶 徐立昌 徐春雨.拉米夫定联合胸腺肽A1 治疗慢性乙型肝炎的疗效观察[J].,2006,6(1):55 |
| 拉米夫定联合胸腺肽A1 治疗慢性乙型肝炎的疗效观察 |
| Clinical Observation of Lamivudine combined with Thymosin A1in Treatment of Patients with Chronic Hepatitis B |
| |
| DOI： |
| 中文关键词: 病毒性肝炎 乙型 胸腺肽A1 拉米夫定 |
| 英文关键词: Chronic hepatitis B( CHB) ThymosinA1( TA1) Lamivudine( LAM) |
| 基金项目: |
|
| 摘要点击次数: 765 |
| 全文下载次数: 500 |
| 中文摘要: |
| 目的: 探讨拉米夫定( LAM) 联合胸腺肽A1( TA1) 治疗慢性乙型肝炎的长期疗效和安全性。方法: 72 例慢性乙肝患者
( HBV- DNA 和HBeAg 均阳性) , 按1: 1 随机分配进入联合治疗组( LAM+ TA1 组) 和单用拉米夫定组( LAM 组) 。结果: 治疗1 年时
LAM+ TA1 组HBeAg 血清转换率( 44. 4%, 16/ 36 例) 明显高于LAM 组( 5. 6%, 2/ 36 例) , P< 0. 01。停药1 年后, 持续的HBeAg 血清
转换率分别为36. 1%( 13/ 36 例) 和8. 3%( 3/ 36 例) , P< 0. 01。治疗过程中及停药后, 两组HBV- DNA 水平均明显下降, 但两组的
HBV- DNA 转阴率相仿。治疗后1 年ALT 复常率联合治疗组与拉米夫定组相似, 分别为75% ( 27/ 36 例) 和66. 7%( 24/ 36 例) 、随
访1 年时ALT 复常率联合治疗组明显高于拉米夫定组, 分别为58. 3%( 21/ 36 例) 和16. 7%( 6/ 36 例) 。在治疗过程中, 未发现严
重的不良反应。结论: LAM 联合TA1 治疗慢性乙肝, 不良反应少, 疗效优于单一LAM 用药组。 |
| 英文摘要: |
| Objective: To evaluate the long- term efficacy and safety of lamivudine( LAM) combined with thymosinA1( TA1) in the treatment
of the patients with chronic hepatitis B( CHB) . Methods: 72 CHB patients aged 18 to 56 years ( HBV- DNA and HBeAg, positive) were
randomly divided by 1: 1 proportion into two groups: 36 patients were given LAM alone( dose, 100mg a day, orally, at least for one year) ( i. e.
LAM group) ; 36 patients LAM( usage & dosage, the same as LAM group) plus TA1( starting dose during the first 4 days of half a year cycle, 1.
6mg a day, subcutaneously; after that, 1. 6mg, twice a week) ( i. e. LAM + TA1 group) . Results: At one year, HBeAg seroconversion rate in
LAM + TA1 group was 44. 4%( 16/ 36) , which was significantly higher than that in LAM group( 5. 6%, 2/ 36) ( P< 0. 01) . Through one- year
follow- up after treatment, 58. 3%( 21/ 36) of ALT recovery rate in LAM + TA1 group was obviously higher than that in LAM group( 16. 7%, 6/
36) . Conclusion: The curative effect of LAM + TA1 group, in the treatment of CHB, is superior to that of LAM group, which has little side effects. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
